Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.

CONCLUSION: The cemcitabine and cisplatin combination therapy as first-line treatment of metastatic pancreatic cancer yields significantly prolonged survival over gemcitabine monotherapy. In patients with favorable performance conditions, the combination therapy should be preferred.
PMID: 30722120 [PubMed - in process]

Source: Journal of B.U.ON. - February 7, 2019 Category: Cancer & Oncology Tags: J BUON Source Type: research